Many studies have demonstrated that the therapeutic efficacy of 1st and 2nd generation TKIs is restricted in patients with lung SCC and lung adenocarcinoma that contains EGFR KDD mutations [29–31]. Here, EGFR is linked to lung adenocarcinoma.